Skip to main content

Month: August 2025

Volta Finance Limited Net Asset Value(s) as at 31 July 2025

Volta Finance Limited (VTA / VTAS)July 2025 monthly report NOT FOR RELEASE, DISTRIBUTION, OR PUBLICATION, IN WHOLE OR PART, IN OR INTO THE UNITED STATES Guernsey, August 21st, 2025 AXA IM has published the Volta Finance Limited (the “Company” or “Volta Finance” or “Volta”) monthly report for July 2025. The full report is attached to this release and will be available on Volta’s website shortly (www.voltafinance.com). Performance and Portfolio Activity Dear Investors, In July, Volta Finance achieved a net performance of +2.48% (including a dividend payment of 15.5 cents per share), bringing the Financial Year net performance to +13.9% (August 2024 to July 2025). To frame this performance in perspective with the broader Credit markets, US High Yield returned +8.6% between August 2024 and July 2025, while Euro High Yield returned +8.1% in...

Continue reading

Duluth Holdings Inc. to Report Second Quarter 2025 Financial Results on September 4, 2025

MOUNT HOREB, Wis., Aug. 21, 2025 (GLOBE NEWSWIRE) — Duluth Holdings Inc. (dba, Duluth Trading Company) (“Duluth Trading”) (NASDAQ: DLTH), a lifestyle brand of men’s and women’s casual wear, workwear and accessories, today announced that it will report second quarter 2025 financial results before market on Thursday, September 4, 2025. A conference call and audio webcast with analysts and investors will be held on Thursday, September 4, 2025, at 9:30am Eastern Time to discuss the results and answer questions. Live conference call: 1-844-875-6915 (domestic) or 1-412-317-6711 (international)Conference call replay available through September 10, 2025: 1-877-344-7529 (domestic) or 1-412-317-0088 (international)Replay access code: 1218574 Live and archived webcast: ir.duluthtrading.com To expedite entry into the call and avoid waiting...

Continue reading

Precore Gold Announces up to C$2 Million Private Placement

VANCOUVER, British Columbia, Aug. 21, 2025 (GLOBE NEWSWIRE) — Precore Gold Corp. (CSE: PRCG) (the “Company” or “Precore Gold”) is pleased to announce that it has arranged, subject to receipt of regulatory approval, a non-brokered private placement (the “Private Placement”) to raise gross proceeds of up to $2,000,000. The Private Placement will consist of the sale of up to 11,111,111 units of the Company (the “Units”) at a price of $0.18 per Unit, with each Unit consisting of one common share of the Company (a “Common Share”) and one-half of one share purchase warrant (each whole share purchase warrant, a “Warrant”). Each Warrant will entitle the holder to purchase one additional Common Share (a “Warrant Share”) for a period of thirty-six (36) months at an exercise price of $0.25 per Warrant Share. The Company may pay a finder’s...

Continue reading

WeRide Unveils WePilot AiDrive, A One-Stage End-to-End ADAS Targeted for Mass Production in 2025

GUANGZHOU, China, Aug. 21, 2025 (GLOBE NEWSWIRE) — WeRide (Nasdaq: WRD), a global leader in autonomous driving technology, today launched WePilot AiDrive, its one-stage end-to-end ADAS (Advanced Driver Assistance System) solution. Developed in partnership with leading Tier 1 supplier Bosch, this milestone comes just six months after both companies brought their two-stage end-to-end solution into mass production. Unlike the traditional two-stage process of sensing and then decision-making, WePilot AiDrive integrates both into a one-stage architecture, enabling vehicles to “see and act” at the same time — like a skilled human driver. This delivers faster responses, shorter driving routes, and greater fault tolerance. WePilot AiDrive has completed core function validation and is expected to enter mass production and vehicle...

Continue reading

Kaldalón hf.: Bill Auction Announcement

On Monday, 25 August, Kaldalón hf. will auction six-month bills in a new series, KALD 26 0302 bills. The auction is held in line with the company’s policy to be a regular issuer of bills and bonds. The auction will be conducted using the Dutch method, i.e. all accepted bids will be sold to investors at the highest accepted flat yield. The bills will be issued in nominal value units of ISK 20 million. The company reserves the right to accept all bids, reject all bids, or accept bids in part. The results of the auction and allocation to investors will be announced no later than prior to market opening on Tuesday, 26 August. Landsbankinn hf. will manage the auction. Bids, stating nominal amount and flat yield, must be submitted to Landsbankinn hf. no later than 16:00 on Monday, 25 August, at the email address: verdbrefamidlun@landsbankinn.is.Payment...

Continue reading

Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®

Mynzepli® (aflibercept) is approved in all European Economic Area member countries for the treatment of various retinal diseases including neovascular (wet) age-related macular degeneration (AMD)Approval is based on comprehensive analytical, non-clinical and clinical similarity data, including a confirmatory efficacy study comparing Mynzepli® with the reference biologic Eylea® in patients with neovascular AMDREYKJAVIK, ICELAND and LONDON, UK (August 21, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Commission...

Continue reading

Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®

Mynzepli® (aflibercept) is approved in all European Economic Area member countries for the treatment of various retinal diseases including neovascular (wet) age-related macular degeneration (AMD)Approval is based on comprehensive analytical, non-clinical and clinical similarity data, including a confirmatory efficacy study comparing Mynzepli® with the reference biologic Eylea® in patients with neovascular AMDREYKJAVIK, Iceland and LONDON, Aug. 21, 2025 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European...

Continue reading

Columbus Interim Report Q2 2025

Company announcement no. 17/2025 Market caution reflected in Q2 resultsColumbus experienced increased macro-economic headwinds in Q2 2025, leading to prolonged sales cycles and postponed IT project decisions. As a result, revenue decreased by 4% and EBITDA amounted to DKK 16m in Q2 2025, corresponding to an EBITDA margin of 4%, compared to 7% in Q2 2024. Despite the decline in revenue, we maintain a stable operational business with positive cashflow from operating activities, up 15% compared with Q2 2024. The outlook for 2025 has been adjusted to reflect current market conditions. “While the current market conditions require us to adjust our short-term expectations, we remain confident in Columbus’ long-term growth potential and continue to execute our New Heights strategy with discipline and focus,” says CEO & President, Søren Krogh...

Continue reading

cBrain® advances global growth strategy, maintaining long-term focus

Company Announcement no. 08/2025 cBrain® advances global growth strategy, maintaining long-term focus   Copenhagen, August 21, 2025   We are now entering the final half year of our 2023–2025 growth plan. We see standard software for government evolving into a large industry, challenging the dominance of traditional suppliers. With more than 15 years of experience, a strong product position, and solid customer references, we look confidently toward the next decade. We aim to take a leadership position within the commercial off-the-shelf (COTS) software for government industry, and we have refined our strategy accordingly. Our dual go-to-market approach balances depth with focus: we continue to build our core business around large account customers (“super accounts”), while in parallel pursuing global leadership in selected niches where...

Continue reading

Vow ASA: Invitation to presentation of second quarter and first half year 2025

Vow ASA (OSE: VOW) will release its report for the second quarter and first half year 2025 on Thursday 28 August 2025. The update will be published on https://newsweb.oslobors.no/ and on the company’s web site www.vowasa.com. Vow ASA is pleased to invite shareholders, investors, analysts, and other interested parties to a presentation of the results and a Q&A at 09:00 CET on the same day. Personal attendance is welcomed at Haakon VII’s gate 2, 0161 Oslo. The session will also be streamed via webcast. To register and follow the presentation online, please copy and paste the following link into your browser, click Attend and register your e-mail: https://channel.royalcast.com/landingpage/hegnarmedia/20250828_3/ For further information, please contact: Gunnar Pedersen, CEO, Vow ASA Tel: +47 91 63 03 04 Email: gunnar.pedersen@vowasa.com Cecilie...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.